INDACATEROL - THE NEWEST AND THE FIRST ONCE-DAILY-B2-AGONIST FOR THE TREATMENT OF COPD

  • Mindaugas Vaitkus
DOI: https://doi.org/10.37499/PIA.416
Keywords: long-acting β2 agonist, chronic obstructive pulmonary disease, inhalation therapy, Indacaterol, Onbrez® Breezehaler®

Abstract

Indacaterol is a new once-daily maintenance broncholdilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease. It has a relatively longer duration of action compared with existing long acting β2-agonists and a fast onset of action.

Author Biography

Mindaugas Vaitkus

Department of Pulmonology and Immunology, Medical Academy, Lithuanian University of Health Sciences

How to Cite
1.
Vaitkus M. INDACATEROL - THE NEWEST AND THE FIRST ONCE-DAILY-B2-AGONIST FOR THE TREATMENT OF COPD [Internet]. PIA 2012 May;10(1):50-54.[cited 2024 Nov. 22 ] Available from: http://pia.pulmoalerg.lt/index.php/PIA/article/view/416
Issue
Vol 10 No 1 (2012): Pulmonology, Immunology and Allergology
Section
Pharmacotherapy